PHILADELPHIA, January 07, 2026--(BUSINESS WIRE)--iECURE, Inc., a genome editing company focused on the development of variant-agnostic in vivo targeted gene insertion therapies for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results